1. Home
  2. COUR vs ELVN Comparison

COUR vs ELVN Comparison

Compare COUR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COUR
  • ELVN
  • Stock Information
  • Founded
  • COUR 2012
  • ELVN 2016
  • Country
  • COUR United States
  • ELVN United States
  • Employees
  • COUR N/A
  • ELVN N/A
  • Industry
  • COUR Computer Software: Prepackaged Software
  • ELVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • COUR Technology
  • ELVN Health Care
  • Exchange
  • COUR Nasdaq
  • ELVN Nasdaq
  • Market Cap
  • COUR 1.2B
  • ELVN 1.1B
  • IPO Year
  • COUR 2021
  • ELVN 2020
  • Fundamental
  • Price
  • COUR $8.32
  • ELVN $22.47
  • Analyst Decision
  • COUR Buy
  • ELVN Strong Buy
  • Analyst Count
  • COUR 13
  • ELVN 5
  • Target Price
  • COUR $11.17
  • ELVN $37.80
  • AVG Volume (30 Days)
  • COUR 3.2M
  • ELVN 204.7K
  • Earning Date
  • COUR 01-30-2025
  • ELVN 11-13-2024
  • Dividend Yield
  • COUR N/A
  • ELVN N/A
  • EPS Growth
  • COUR N/A
  • ELVN N/A
  • EPS
  • COUR N/A
  • ELVN N/A
  • Revenue
  • COUR $684,374,000.00
  • ELVN N/A
  • Revenue This Year
  • COUR $11.00
  • ELVN N/A
  • Revenue Next Year
  • COUR $6.69
  • ELVN N/A
  • P/E Ratio
  • COUR N/A
  • ELVN N/A
  • Revenue Growth
  • COUR 12.36
  • ELVN N/A
  • 52 Week Low
  • COUR $6.29
  • ELVN $10.90
  • 52 Week High
  • COUR $20.73
  • ELVN $30.03
  • Technical
  • Relative Strength Index (RSI)
  • COUR 54.91
  • ELVN 39.53
  • Support Level
  • COUR $7.80
  • ELVN $21.84
  • Resistance Level
  • COUR $9.04
  • ELVN $24.42
  • Average True Range (ATR)
  • COUR 0.42
  • ELVN 1.59
  • MACD
  • COUR -0.02
  • ELVN -0.05
  • Stochastic Oscillator
  • COUR 41.94
  • ELVN 18.27

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Share on Social Networks: